app.rxdatalab.com · Free public feature
Regulatory filings linked to clinical programs and markets. Trials, SEC filings, insider activity, and market data from primary sources.
BioHedge
Hedge fund positioning from Schedule 13D/13G filings. Each position cross-referenced with clinical trial events, regulatory filings, and insider trades. Free public view — the full platform adds company profiles, trial history, competitive landscape, and financing tracker for 500+ biotech companies.
Activity Summary
Multi-Fund Activity
Companies with two or more institutional investors filing in the same period.
Filing Volume by Week
|
Filed
|
Fund | Company | Position | Gap |
|---|---|---|---|---|
|
Jul 10, 2026
Event: 07/02/2026
Filed: Jul 10, 2026 |
PYXS
Pyxis Oncology, Inc.
|
owns 10.0% NEW | — | |
|
PYXS
Pyxis Oncology, Inc.
10.0%
NEW
|
||||
|
Jul 8, 2026
Event: 07/01/2026
Filed: Jul 8, 2026 |
ANNX
Annexon, Inc.
|
owns 9.9% | 141d | |
|
ANNX
Annexon, Inc.
9.9%
141d
|
||||
|
Jul 7, 2026
Event: 07/02/2026
Filed: Jul 7, 2026 |
CLYM
CLIMB BIO INC
|
owns 33.0% | 69d | |
|
CLYM
CLIMB BIO INC
33.0%
69d
|
||||
|
Jul 6, 2026
Event: 07/01/2026
Filed: Jul 6, 2026 |
BBOT
BRIDGEBIO ONCOLOGY THERAPEUT
|
owns 22.3% | — | |
|
BBOT
BRIDGEBIO ONCOLOGY THERAPEUT
22.3%
|
||||
|
Jul 2, 2026
Event: 05/14/2026
Filed: Jul 2, 2026 |
ALMS
ALUMIS INC.
|
owns 12.3% ▼-3.5 | 405d | |
|
ALMS
ALUMIS INC.
12.3%
▼-3.5
405d
|
||||
|
Jul 2, 2026
Event: 06/30/2026
Filed: Jul 2, 2026 |
PYXS
Pyxis Oncology, Inc.
|
owns 12.1% ▲5.9 | 282d | |
|
PYXS
Pyxis Oncology, Inc.
12.1%
▲5.9
282d
|
||||
|
Jul 2, 2026
Event: 06/25/2026
Filed: Jul 2, 2026 |
PASG
PASSAGE BIO INC
|
owns 21.0% NEW | 230d | |
|
PASG
PASSAGE BIO INC
21.0%
NEW
230d
|
||||
|
Jul 2, 2026
Event: 06/30/2026
Filed: Jul 2, 2026 |
HOWL
Werewolf Therapeutics, Inc.
|
owns 4.1% ▼-1.9 | 6d | |
|
HOWL
Werewolf Therapeutics, Inc.
4.1%
▼-1.9
6d
|
||||
|
Jul 1, 2026
Event: 07/01/2026
Filed: Jul 1, 2026 |
ORKA
Oruka Therapeutics, Inc.
|
owns 19.5% ▼-0.5 | 58d | |
|
ORKA
Oruka Therapeutics, Inc.
19.5%
▼-0.5
58d
|
||||
|
Jun 29, 2026
Event: 06/25/2026
Filed: Jun 29, 2026 |
MLTX
MoonLake Immunotherapeutics
|
owns 19.7% ▼-2.6 | 88d | |
|
MLTX
MoonLake Immunotherapeutics
19.7%
▼-2.6
88d
|
||||
Understanding Schedule 13D and 13G Filings
Schedule 13D and 13G filings are SEC disclosures required when an investor acquires more than 5% of a company's outstanding shares.
Schedule 13D (Activist)
Filed when an investor may seek to influence management, board composition, or corporate strategy. Requires disclosure of investment purpose and plans.
Schedule 13G (Passive)
Filed by passive investors (mutual funds, index funds, institutions) with no intent to influence. Simpler filing requirements.
Gap column: Days since previous filing for the same fund+company pair.
Data source: SEC EDGAR. Filings typically available within 4 hours of submission.
This page reflects disclosed ownership changes only. Absence of activity does not imply absence of interest.
Intelligence Platform
Every event, in context.
Cross-reference each company's trial history, SEC filings, insider trades, and fund positioning in one view. Traceable to primary sources.